Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Language menu
  5. Go to Help menu
  6. Go to modules
  7. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

R&D

Sub-section menu :

Contact us

Sanofi

Units 706-710, Level 7,
Core C, Cyberport 3,
100 Cyberport Road,
Hong Kong

Tel.: (852) 2506 8333
Fax: (852) 2506 2537

Content :

Research & Development

Sanofi ’s R&D ambition is to provide patients with effective and well-tolerated medicines and vaccines, as rapidly as possible, in those therapeutic areas where there are major healthcare needs.

 

These areas represent the leading causes of mortality worldwide: thrombosis and cardiovascular disease, metabolic disorders, cancer, internal medicine, central nervous system disorders, and infectious diseases. With regard to these therapeutic areas, the Group has a dual approach which is both curative through the development of new medicines or new indications, and preventative, with the design and development of innovative vaccines.

With 18,981 Research & Development staff and more than 25 R&D centres on three continents, Sanofi now has one of the most fertile and innovative R&D portfolios in the pharmaceutical industry, including 125 compounds and vaccines in development, of which 46 are in Phases IIb or III of clinical development.

Today, 30 to 40% of the Sanofi's R&D portfolio comprises “first in class” compounds which, as far as the Group is aware, have mechanisms of action that have no equivalent among products which are currently on the market or in development

Development phases

R&D encompasses every phase, starting with understanding a disease and its biological foundations up to and including marketing a new medication, which usually spans across 12 years.

Research: 2-4 years

Identifying new compounds or substances able to cure, relieve, or prevent a disease.

Preclinical Development: 1-2 years

Improving the properties and activity of products which research has identified.

Clinical Development: 6-8 years

Testing the new compound in humans:

  • Phase I: Evaluation of drug tolerance in a healthy human (a few dozen volunteers)

  • Phase II: Evaluation of drug efficacy in patients. Determination of an effective dose (a few hundred patients)

  • Phase III: Evaluation of medication in a large number of patients. Comparison with existing treatment and/ or reference treatment (a few thousand patients)

Registration: 1 year

Obtain administrative approval from local health authorities to market the drug

Updated January 01, 2008